Tomasselli A G, Paddock D J, Emmons T L, Mildner A M, Leone J W, Lull J M, Cialdella J I, Prince D B, Fischer H D, Heinrikson R L, Benson T E
Global Research and Development, St. Louis Laboratories, Pfizer Inc., Chesterfield, MO 63017, USA.
Protein Pept Lett. 2008;15(2):131-43. doi: 10.2174/092986608783489553.
BACE (beta-site APP cleaving enzyme) or beta-secretase, the enzyme responsible for processing APP to give the N-terminal portion of the Abeta peptide, is a membrane bound aspartyl protease consisting of an ectodomain catalytic unit, a C-terminal transmembrane segment and a cytoplasmic domain. Three BACE constructs, pET11a-BACE, pQE80L-BACE, and pQE70-BACE were designed to terminate at a position just before the transmembrane domain (Ser(432)) and are described schematically below. (1) pET11a-T7.Tag-G-S-M-(A-8GV......QTDES(432)), (2) pQE80L-Met-R-G-S-(His)(6)-G-S-I-E-T-D-(T(1)QH...QTDES(432)), and (3) pQE70-Met-BACE (R(36)GSFVEMG....PQTDES(432) (His) (6)) Each construct was over-expressed in Escherichia coli as inclusion bodies. The inclusion body proteins were solubilized in urea and refolded by dilution in water to yield active enzyme. Maximal activity for pET11a-BACE and pQE80L-BACE was usually reached at day 3 to 4, while construct pQE70-BACE required about 21 days. Active BACE was purified to homogeneity by anion-exchange chromatography and affinity chromatography over a column of immobilized peptide inhibitor. The process, easily scalable to 60 liters of cell culture, yielded in excess of 400 mg of active enzyme for crystallographic analysis. Highly purified pET11a-BACE and pQE70-BACE formed complexes with various inhibitors, the latter protein giving crystals diffracting up to 1.45 A resolution. In addition, a crystal form that does not require the presence of an inhibitor has been obtained for pQE70-BACE. This ligand-free crystal form has proven useful for the preparation of BACE-inhibitor complexes in soaking experiments.
β-位点淀粉样前体蛋白裂解酶(BACE),即β-分泌酶,是一种负责加工淀粉样前体蛋白(APP)以生成Aβ肽N端部分的酶,它是一种膜结合天冬氨酸蛋白酶,由一个胞外结构域催化单元、一个C端跨膜片段和一个胞质结构域组成。设计了三种BACE构建体,即pET11a-BACE、pQE80L-BACE和pQE70-BACE,使其在跨膜结构域(Ser(432))之前的位置终止,其示意图如下所述。(1)pET11a-T7.Tag-G-S-M-(A-8GV......QTDES(432)),(2)pQE80L-Met-R-G-S-(His)(6)-G-S-I-E-T-D-(T(1)QH...QTDES(432)),以及(3)pQE70-Met-BACE (R(36)GSFVEMG....PQTDES(432) (His) (6))。每种构建体在大肠杆菌中作为包涵体进行过表达。包涵体蛋白在尿素中溶解,并通过用水稀释进行复性以产生活性酶。pET11a-BACE和pQE80L-BACE的最大活性通常在第3至4天达到,而构建体pQE70-BACE则需要约21天。活性BACE通过阴离子交换色谱和固定化肽抑制剂柱上的亲和色谱纯化至均一性。该过程易于放大至60升细胞培养,产生超过400毫克的活性酶用于晶体学分析。高度纯化的pET11a-BACE和pQE70-BACE与各种抑制剂形成复合物,后者的蛋白质产生衍射分辨率高达至1.45 Å的晶体。此外,已获得一种不需要抑制剂存在的pQE70-BACE晶体形式。这种无配体晶体形式已被证明在浸泡实验中用于制备BACE-抑制剂复合物很有用。